Peter Rahmer sold $100k of RLAY
See remarks at Relay Therapeutics, Inc.. 13,038 shares at an average of $7.71, traded Jan 27, 2026, filed Jan 29, 2026.
Score components
- +15RoleOfficer
- +10Trade size$100k at market
- 0Share of holdings soldSold 4.5% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +33.1%, 3m +68.1%, 6m +152.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-029412, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | AGrant or award Common Stock | +994 | $2.99 | $2,972 | 338,463 | Jan 29, 2026 |
| Jan 27, 2026 | SOpen-market sale Common Stock | -11,684 | $7.62 | $89k | 277,964 | Jan 29, 2026 |
| Jan 28, 2026 | SOpen-market sale Common Stock | -1,354 | $8.45 | $11k | 276,610 | Jan 29, 2026 |
Related signals
Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $329k 17,717 shares | -14% | |
| Pro nowfree Oct 15, 2026 | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $872k 48,199 shares | -9% | |
| 26Weak | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $162k 8,530 shares | -2% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $336k 17,717 shares | -13% | |
| 44Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $913k 48,199 shares | -8% | |
| 19Weak | Relay Therapeutics, Inc. | Peter Rahmer See remarks | $90k 4,508 shares | -2% | |
| 57Moderate | Relay Therapeutics, Inc. | SVF Pauling (Cayman) Ltd owner | $116M 6,000,000 shares | -22% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $350k 17,717 shares | -11% | |
| 45Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $980k 48,199 shares | -8% | |
| 41Moderate | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $42k 2,237 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.